Testing the wrong hypothesis in phase II oncology trials: There is a better alternative. Commentary on Vickers et al., p. 972

Clinical Cancer Research

Volumn 13, Issue 3, 2007, Pages 781-782

  Ratain, Mark J ^a   Karrison, Theodore G ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ERLOTINIB; GEMCITABINE;

ACCURACY; ALTERNATIVE HYPOTHESIS; BILE DUCT CANCER; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; EDITORIAL; HEALTH CARE ORGANIZATION; HUMAN; MESOTHELIOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

CLINICAL TRIALS, PHASE II; HUMANS; MEDICAL ONCOLOGY; MODELS, THEORETICAL; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 33847415407     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2533     Document Type: Editorial

References (11)

1. Temple R. Current definitions of phases of investigation and the role of the FDA in the conduct of clinical trials. Am Heart J 2000;139:S133-5.
2. Gehan EA. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 1961;13:346-53.
3. Ratain MJ, Mick R, Schilsky RL, Siegler M. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst 1993;85:1637-43.
4. Fleming TR. One-sample multiple testing procedure for phase Il clinical trials. Biometrics 1982;38:143-51.
5. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989;10:1-10.
6. Vickers AJ, Ballen V, Scher HI. Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing. Clin Cancer Res 2007;13:972-6.
7. Utkan G, Buyukcelik A, Yalcin B, et al. Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma. Lung Cancer 2006;53:367-74.
8. Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 2006;24:3069-74.
9. Ratain MJ. Phase II oncology trials: let's be positive. Clin Cancer Res 2005;11:5661-2.
10. Michaelis LC, Ratain MJ. Measuring response in a post-RECIST world: from black and white to shades of grey. Nat Rev Cancer 2006;6:409-14.
11. Booth B, Glassman R, Ma P. Oncology's trials. Nat Rev Drug Discov 2003;2:609-10.